Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Go back to Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026| AGENUS (NASDAQ: AGEN) | Delayed: 3.12 +0.08 (2.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.04 | 52 Week High | $7.49 | |||
| Open | $2.99 | 52 Week Low | $2.61 | |||
| Day High | $3.18 | P/E | N/A | |||
| Day Low | $2.99 | EPS | $-1.10 | |||
| Volume | 148,699 | |||||
| (NASDAQ: INKT) | Delayed: 12.37 +0.12 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.25 | 52 Week High | $ | |||
| Open | $11.88 | 52 Week Low | $ | |||
| Day High | $12.42 | P/E | N/A | |||
| Day Low | $11.88 | EPS | $ | |||
| Volume | 8,858 | |||||
